Oral minoxidil is effective for hair loss but may cause side effects like increased heart rate and edema. Finasteride is recommended, with dutasteride as an alternative if needed.
Finasteride and minoxidil are used together for hair regrowth, as finasteride blocks DHT and minoxidil enhances blood flow. Some hair types require both treatments for regrowth, while others may only need one.
Long-term finasteride use typically slows hair loss, with some users experiencing side effects like sexual dysfunction and depression. Many users also use minoxidil and dutasteride for improved results, though individual responses vary.
A 24-year-old reported new hair growth on temples after 3.5 months of using topical minoxidil without shedding. They plan to add finasteride to maintain progress, as minoxidil alone may not be enough long-term.
Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.
Users discuss their experiences with dutasteride for hair loss, noting varying results such as regrowth, shedding, and side effects. Some users also mention using finasteride, minoxidil, and microneedling, with mixed outcomes on hair quality and side effects.
The user is frustrated with ongoing hair loss despite using treatments like dutasteride, finasteride, and minoxidil, and is considering shaving their head. They are advised to maintain consistency with medication, consider oral minoxidil, and explore hair transplant options.
PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.
The user is attempting to regrow hair using natural methods like microneedling, rosemary oil, and capsaicin tincture, avoiding medications like finasteride and minoxidil due to past health issues. Feedback suggests these methods are ineffective, with many recommending shaving or considering a hair system instead.
Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.